---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-091801"
form_type: "8-K"
ticker: "MYO"
cik: "0001369290"
company_name: "MYOMO, INC."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:12:03.704039+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Myomo Q2 2024 revenue $7.5M (+77% product revenue); record 213 MyoPro orders

## Summary
- Product revenue $7.5M (+77% YoY); total revenue $7.5M (+26% YoY) reflecting prior-year license fee.
- Record 213 MyoPro authorizations/orders (+70% YoY); backlog 282 units (+58% YoY).
- 1,179 patients in pipeline (+22% YoY); 550 new candidates added in Q2 (+35% YoY).
- Gross margin 70.8% (product GM up 1,030 bps to 70.8%); net loss $1.1M ($0.03 EPS).
- Q3 revenue guidance $8.0-8.5M; FY2024 revenue target $28-30M; targeting Q4 operating cash flow breakeven.

## SEC filing metadata
- accession: 0000950170-24-091801
- form_type: 8-K
- ticker: MYO
- cik: 0001369290
- company_name: MYOMO, INC.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1369290/000095017024091801/0000950170-24-091801-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1369290/000095017024091801/myo-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-091801
- JSON: https://secwatch.observer/filing/0000950170-24-091801.json
- Plain text: https://secwatch.observer/filing/0000950170-24-091801.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.